{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:36:40Z","timestamp":1791128200962,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1124\/jpet.118.254904","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T16:45:20Z","timestamp":1553100320000},"page":"318-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid\u2013Related Disease"],"prefix":"10.1016","volume":"369","author":[{"given":"Dong Kyu","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Hye","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong-Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geun-Seog","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung-Seok","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Young","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.118.254904_bib1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pharmthera.2005.05.005","article-title":"Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases","volume":"108","author":"Andersson","year":"2005","journal-title":"Pharmacol Ther"},{"issue":"Suppl 5","key":"10.1124\/jpet.118.254904_bib2","first-page":"S125","article-title":"Nocturnal acid breakthrough: clinical significance and management","volume":"21","author":"Ang","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1124\/jpet.118.254904_bib3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","article-title":"Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis","volume":"43","author":"Ashida","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.118.254904_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1476-5381.1986.tb09466.x","article-title":"Mechanism of gastric antisecretory effect of SCH 28080","volume":"88","author":"Beil","year":"1986","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.118.254904_bib5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/gut.33.1.118","article-title":"Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease","volume":"33","author":"Bell","year":"1992","journal-title":"Gut"},{"key":"10.1124\/jpet.118.254904_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0016-5085(90)91015-X","article-title":"Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression","volume":"99","author":"Burget","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.118.254904_bib7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/0041-008X(65)90010-4","article-title":"A one-year study of the toxicity of ethambutol in dogs: results of gross and histopathologic examinations","volume":"7","author":"Cappiello","year":"1965","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/jpet.118.254904_bib8","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.3748\/wjg.v19.i39.6529","article-title":"Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease","volume":"19","author":"Cicala","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1124\/jpet.118.254904_bib9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/00042737-199911000-00016","article-title":"Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion","volume":"11","author":"Dammann","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1124\/jpet.118.254904_bib10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2036.2006.03074.x","article-title":"Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs","volume":"24","author":"Edwards","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.118.254904_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","article-title":"Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next?","volume":"22","author":"Fass","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.118.254904_bib12","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJM199012133232405","article-title":"Histamine H2 receptor antagonists","volume":"323","author":"Feldman","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.118.254904_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0962-8924(96)81009-9","article-title":"The membrane-recruitment-and-recycling hypothesis of gastric HCl secretion","volume":"6","author":"Forte","year":"1996","journal-title":"Trends Cell Biol"},{"key":"10.1124\/jpet.118.254904_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2036.2003.01405.x","article-title":"Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole","volume":"17","author":"Frazzoni","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.118.254904_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2133\/dmpk.20.153","article-title":"Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies","volume":"20","author":"Furuta","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/jpet.118.254904_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","article-title":"Vonoprazan: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1124\/jpet.118.254904_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.110.170274","article-title":"1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases","volume":"335","author":"Hori","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.254904_bib18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/jpet.111.179556","article-title":"A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals","volume":"337","author":"Hori","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.254904_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2016.08.001","article-title":"Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases","volume":"168","author":"Inatomi","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.118.254904_bib20","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2007.08.014","article-title":"A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis","volume":"5","author":"Kahrilas","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/jpet.118.254904_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2036.2000.00775.x","article-title":"Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole","volume":"14","author":"Katz","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.118.254904_bib22","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1016\/S0021-9258(18)83580-3","article-title":"The binding of a K+ competitive ligand, 2-methyl,8-(phenylmethoxy)imidazo(1,2-a)pyridine 3-acetonitrile, to the gastric (H+ + K+)-ATPase","volume":"264","author":"Keeling","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.118.254904_bib23","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1440-1746.2010.06408.x","article-title":"Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects","volume":"25","author":"Kim","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1124\/jpet.118.254904_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13876","article-title":"Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials","volume":"45","author":"Miwa","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.118.254904_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1124\/jpet.108.146415","article-title":"N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease","volume":"328","author":"Mori","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.254904_bib26","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","article-title":"Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study","volume":"65","author":"Murakami","year":"2016","journal-title":"Gut"},{"key":"10.1124\/jpet.118.254904_bib27","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0022-3565(25)23774-0","article-title":"Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749","volume":"248","author":"Nagaya","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.254904_bib28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/13543784.14.4.411","article-title":"Novel approaches to the pharmacological blockade of gastric acid secretion","volume":"14","author":"Parsons","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.118.254904_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.ph.52.030190.001541","article-title":"The mechanism and structure of the gastric H,K-ATPase","volume":"52","author":"Rabon","year":"1990","journal-title":"Annu Rev Physiol"},{"key":"10.1124\/jpet.118.254904_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejphar.2008.04.062","article-title":"Effect of quercetin, flavonoids and \u03b1-tocopherol, an antioxidant vitamin, on experimental reflux oesophagitis in rats","volume":"589","author":"Rao","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 6","key":"10.1124\/jpet.118.254904_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2036.2004.02160.x","article-title":"Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors\u2014overview and clinical implications","volume":"20","author":"Robinson","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.118.254904_bib32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1368-5031.2005.00517.x","article-title":"Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases","volume":"59","author":"Robinson","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1124\/jpet.118.254904_bib33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.pa.28.040188.001413","article-title":"Gastric H,K-ATPase as therapeutic target","volume":"28","author":"Sachs","year":"1988","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.118.254904_bib34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.pa.35.040195.001425","article-title":"The pharmacology of the gastric acid pump: the H+,K+ ATPase","volume":"35","author":"Sachs","year":"1995","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.118.254904_bib35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11894-010-0149-5","article-title":"Novel approaches to inhibition of gastric acid secretion","volume":"12","author":"Sachs","year":"2010","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1124\/jpet.118.254904_bib36","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/apt.13414","article-title":"The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase","volume":"42","author":"Scott","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.118.254904_bib37","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1053\/gast.2002.36593","article-title":"Restoration of acid secretion following treatment with proton pump inhibitors","volume":"123","author":"Shin","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.118.254904_bib38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/jpet.117.244202","article-title":"Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility","volume":"364","author":"Takahashi","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.254904_bib39","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1365-2036.2004.01957.x","article-title":"Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease","volume":"19","author":"Vakil","year":"2004","journal-title":"Aliment Pharmacol Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524259899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524259899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.118.254904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:00:13Z","timestamp":1739962813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524259899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0022356524259899"],"URL":"https:\/\/doi.org\/10.1124\/jpet.118.254904","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid\u2013Related Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.118.254904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}